{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:50:59Z","timestamp":1788360659979,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hydroxyurea (HU) is a cytostatic drug used in oncotherapy. The drug has inhibitory effects on bone marrow and epithelial cells and causes minor side effects in the skin, including nail deformity, alopecia, and hyperpigmentation, and severe side effects, including skin tumors and nonhealing ulcers. Herein, we report the case of a patient who received HU therapy for polycythemia vera. The patient had type 2 diabetes and atherosclerosis. Onychodystrophy and a non-healing ulcer developed. Severe deep tissue infection and osteomyelitis, rare complications of a HU-related ulcer, were also diagnosed later. Diabetes and atherosclerosis made the condition more severe. Complex systemic and local therapy led to complete healing of the ulcer and osteomyelitis. Based on the literature and our own experience, a care protocol was proposed for the dermatological follow-up of patients under HU treatment. This recommendation may be particularly useful in the treatment of patients treated with hydroxyurea who suffer from atherosclerosis, diabetes, or leg ulcers and are therefore at increased risk of severe skin and deep tissue infections.<\/jats:p>","DOI":"10.3390\/jcm14248637","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Limb Salvage After Deep Tissue Infection Associated with Hydroxyurea Therapy and Recommendations for a Follow-Up Protocol in Patients Treated with Hydroxyurea"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6571-0308","authenticated-orcid":false,"given":"\u00c9va","family":"Badak","sequence":"first","affiliation":[{"name":"Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"General Practice, 7039 N\u00e9metk\u00e9r, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Bodn\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Outpatient Centre, 4200 Hajd\u00faszoboszl\u00f3, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7099-6718","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"Vir\u00e1g","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"HUN-REN-DE Cell Biology and Signaling Research Group, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Remenyik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Singh, A., and Xu, Y.J. (2016). The Cell Killing Mechanisms of Hydroxyurea. Genes, 7.","DOI":"10.3390\/genes7110099"},{"key":"ref_3","first-page":"1","article-title":"Mechanism of action of hydroxyurea","volume":"19","author":"Yarbro","year":"1992","journal-title":"Semin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/0192623314559103","article-title":"Toxicity of hydroxyurea in rats and dogs","volume":"43","author":"Morton","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archderm.1975.01630140041002","article-title":"Skin changes secondary to hydroxyurea therapy","volume":"111","author":"Kennedy","year":"1975","journal-title":"Arch Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"bcr2014205974","DOI":"10.1136\/bcr-2014-205974","article-title":"Photodermatosis secondary to hydroxyurea","volume":"2014","author":"Yanamandra","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ijd.15302","article-title":"Hydroxyurea: A reappraisal of its cutaneous side effects and their management","volume":"60","author":"Bulte","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.12998\/wjcc.v7.i23.4091","article-title":"Hydroxyurea-induced cutaneous squamous cell carcinoma: A case report","volume":"7","author":"Xu","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","article-title":"Hydroxyurea-induced leg ulceration in 14 patients","volume":"128","author":"Best","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1503\/cmaj.081042","article-title":"Hydroxyurea-induced ulcers on the leg","volume":"180","author":"Dissemond","year":"2009","journal-title":"CMAJ"},{"key":"ref_11","first-page":"217","article-title":"Hydroxyurea and lower leg ulcers","volume":"52","author":"Nguyen","year":"1993","journal-title":"Cutis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/archderm.135.7.818","article-title":"Leg ulcers and hydroxyurea: Forty-one cases","volume":"135","author":"Sirieix","year":"1999","journal-title":"Arch. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0190-9622(98)70394-9","article-title":"Leg ulcers associated with long-term hydroxyurea therapy","volume":"39","author":"Weinlich","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/iwj.13115","article-title":"Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?","volume":"16","author":"Soya","year":"2019","journal-title":"Int. Wound J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Alshurafa, A., Alkhatib, M., Abu-Tineh, M., and Yassin, M.A. (2023). Sickle cell leg ulcer successfully managed by hyperbaric oxygen: A case report. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1171971"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s40265-015-0470-2","article-title":"Ruxolitinib: A Review in Polycythaemia Vera","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"ref_17","first-page":"271","article-title":"A case for diagnosis: Ulceration of the skin caused by hydrea","volume":"123","author":"Esteve","year":"1996","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0002-9343(85)90297-9","article-title":"Vasculitic leg ulcers in chronic myelogenous leukemia","volume":"78","author":"Stahl","year":"1985","journal-title":"Am. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jjco\/hyd032","article-title":"A case of bilateral heel ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia","volume":"30","author":"Tarumoto","year":"2000","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/030089168607200314","article-title":"Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia","volume":"72","author":"Montefusco","year":"1986","journal-title":"Tumori"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mvr.2014.05.009","article-title":"In vitro and in vivo anti-angiogenic effects of hydroxyurea","volume":"94","author":"Lopes","year":"2014","journal-title":"Microvasc. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0190-9622(91)70233-R","article-title":"Hydroxyurea therapy","volume":"25","author":"Boyd","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09537100400020179","article-title":"Toxicity and side effects of hydroxyurea used for primary thrombocythemia","volume":"16","author":"Randi","year":"2005","journal-title":"Platelets"},{"key":"ref_24","unstructured":"Swain, D. (2014). Treating a rare foot ulcer caused by hydroxyurea. Podiatry Today, 27, Available online: https:\/\/www.hmpgloballearningnetwork.com\/site\/podiatry\/treating-rare-foot-ulcer-caused-hydroxyurea."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Berlanga-Acosta, J.A., Guillen-Nieto, G.E., Rodriguez-Rodriguez, N., Mendoza-Mari, Y., Bringas-Vega, M.L., Berlanga-Saez, J.O., Garcia Del Barco Herrera, D., Martinez-Jimenez, I., Hernandez-Gutierrez, S., and Valdes-Sosa, P.A. (2020). Cellular Senescence as the Pathogenic Hub of Diabetes-Related Wound Chronicity. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.573032"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e003140","DOI":"10.1136\/bmjdrc-2022-003140","article-title":"Association of arterial stiffness and neuropathy in diabetes: A systematic review and meta-analysis","volume":"11","author":"Beros","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.12968\/jowc.2022.31.10.882","article-title":"Impaired wound healing in diabetes","volume":"31","author":"Swoboda","year":"2022","journal-title":"J. Wound Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.idc.2020.10.007","article-title":"Skin and Soft Tissue Infections in Patients with Diabetes Mellitus","volume":"35","author":"Polk","year":"2021","journal-title":"Infect. Dis. Clin. N. Am"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:47:20Z","timestamp":1765212440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":28,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248637"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248637","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}